Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Merck & Co. to Slash Another 2,500 Jobs as Part of Company Restructuring

Merck & Co. (MRK) has its eyes set on eliminating another 2,500 jobs as part of its ongoing restructuring plan announced in 2013, according to a recent filing with the U.S. Securities and Exchange Commission.   According to the filing, the company said “approximately 2,585 position eliminations remain pending under this program as of June […]

Read More »

Esperion Rockets as Lead Drug ETC-1002 Will Not Require Heart Trial for FDA Approval

Ann Arbor, Mich.-based Esperion Therapeutics, Inc. (ESPR), announced yesterday that the U.S. Food and Drug Administration (FDA) confirmed LDL-C as an acceptable clinical surrogate endpoint for its trial therapeutic, ETC-1002.   ETC-1002 is designed to lower cholesterol for patients who have not had success using statins, such as Pfizer Inc. (PFE)’s Lipitor. The compound is […]

Read More »

Illumina partners with private equity firm on gene JV: sources

Gene-sequencing giant Illumina Inc, private equity firm Warburg Pincus LLC and venture capital firm Sutter Hill Ventures have agreed to invest $100 million to seed a new consumer-facing human genome platform called Helix, according to people familiar with the deal. San Francisco-based Helix aims to provide a new kind of environment that will sequence, store […]

Read More »

FDA warns makers of superbug-prone devices over testing violations

Manufacturers of medical devices linked to recent superbug outbreaks at U.S. hospitals skirted a host of testing, manufacturing and reporting requirements, the U.S. Food and Drug Administration said in warning letters to the companies released on Monday. The letters, sent on Aug. 12, cite Olympus Corp Pentax Medical and Fujifilm Holdings Corp with multiple violations […]

Read More »

PharmaCyte Biotech Has Only Scratched the Surface With Its Cell-in-a-Box Technology

BONITA, CA–(Marketwired – August 17, 2015) – PharmaCyte Biotech Inc. (OTCQB: PMCB) has made a name for itself with the company’s potentially game-changing pancreatic cancer treatment, and also as the name behind what could arguably be seen as a cure for type 1 diabetes. What’s been largely unsaid about PharmaCyte Biotech, however, is that the […]

Read More »

Vitamin D In Teens: Don’t Overdo It, Bad Things Might Happen, Mayo Clinic Study

ROCHESTER, Minn. — Dosing obese teens with vitamin D shows no benefits for their heart health or diabetes risk, and could have the unintended consequences of increasing cholesterol and fat-storing triglycerides. These are the latest findings in a series of Mayo Clinic studies in childhood obesity. Seema Kumar, M.D., a pediatric endocrinologist in the Mayo […]

Read More »

FDA Grants Fast Track Designation to ContraFect’s CF-301, the First of Its Lysins, Currently in Development for the Treatment of Staph Aureus Infections, Including MRSA

YONKERS, NY–(Marketwired – Aug 17, 2015) – ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CF-301, the first […]

Read More »

Kite Pharma CEO Refutes Rumors of Death Associated with Experimental Cancer Drug

The death of a patient participating in a Kite Pharma, Inc. (KITE) clinical trial was determined to not be related to the experimental treatment for low-prognosis patients with non-Hodgkin’s lymphoma, Arie Belldegrun, Kite’s chief executive officer said in a conference call this morning.   During the conference call, Belldegrun refuted what he called a “high […]

Read More »

AVEO Oncology Forges $326 Million Antibody Pact With Novartis

AVEO Announces Exclusive Worldwide License Agreement for the Development and Commercialization of AV-380 and Related Antibodies CAMBRIDGE, Mass.–(BUSINESS WIRE)   AVEO Oncology (AVEO) today announced an exclusive, worldwide license agreement with Novartis for the development and commercialization of AVEO’s first-in-class, potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), AV-380, and related antibodies, including […]

Read More »

India, EU working to end trade huff over generic drugs

India and the European Union are taking steps to end a trade row sparked by an EU ban on Indian pharmaceutical products that New Delhi responded to by cancelling talks on a free trade accord with its largest trading partner, officials said. Indian Prime Minister Narendra Modi’s office wrote to the E.U. Trade Commissioner to […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom